Literature DB >> 1329353

Virus inactivation during intravenous immunoglobulin production.

E Hämäläinen1, H Suomela, P Ukkonen.   

Abstract

Effects of time, temperature, pH and stabilizers (i.e. medium) on inactivation of lipid-enveloped model viruses, Semliki Forest and vesicular stomatitis viruses in the production process of intravenous immunoglobulin were investigated on a laboratory scale. The lowering of pH, the raising of temperature and the increasing of incubation time improved the inactivation effect. However, small changes in pH and stabilizer concentrations did not influence the results. Inactivation was not linear and a clear tailing off could be seen. Therefore, for complete virus inactivation incubation times longer than 20 h are necessary. Inactivation took place much more rapidly in intravenous immunoglobulin solution than in intramuscular immunoglobulin solution. Processing steps such as freeze-dying in the presence of ethanol or storage of intramuscular immunoglobulin in the liquid state at pH7 only partially inactivated these viruses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329353     DOI: 10.1111/j.1423-0410.1992.tb01211.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  4 in total

1.  Failure to detect hepatitis C virus (HCV) genome by polymerase chain reaction in human anti-HCV-positive intravenous immunoglobulins.

Authors:  F Dammacco; D Sansonno; A Beardsley; E J Gowans
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

2.  Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.

Authors:  Daniel Suez; Mark Stein; Sudhir Gupta; Iftikhar Hussain; Isaac Melamed; Kenneth Paris; Amy Darter; Christelle Bourgeois; Sandor Fritsch; Heinz Leibl; Barbara McCoy; David Gelmont; Leman Yel
Journal:  J Clin Immunol       Date:  2016-08-31       Impact factor: 8.317

Review 3.  Assessment of the viral safety of antivenoms fractionated from equine plasma.

Authors:  Thierry Burnouf; Elwyn Griffiths; Ana Padilla; Salwa Seddik; Marco Antonio Stephano; José-María Gutiérrez
Journal:  Biologicals       Date:  2004-09       Impact factor: 1.856

4.  Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.

Authors:  M Borte; G Kriván; B Derfalvi; L Maródi; T Harrer; S Jolles; C Bourgeois; W Engl; H Leibl; B McCoy; D Gelmont; L Yel
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.